Neurogastrx, Inc. is a privately held biopharmaceutical company developing transformative therapies for gastrointestinal disorders. The Company’s focus is on enteric nervous system, which is composed of millions of neurons in the gastrointestinal tract that coordinate their activity to generate the muscle contractions that propel waste through the last leg of the digestive system.
Operating independently of the brain and spinal cord, the enteric nervous system contains more neurons than the spinal cord and hosts 90% of the body’s serotonin and 50% of the body’s dopamine and is an attractive target for the treatment of many gastrointestinal disorders.
Neurogastrx’s lead product, NG101, is a D2 antagonist for the treatment of gastroparesis, a debilitating functional gastrointestinal disorder. NG101 is being developed to have an enhanced safety profile and improved bioavailability versus currently approved drugs. The drug is anticipated to enter phase 2 proof of concept trials beginning in 2019.